12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis.

      Cancer Cell
      Animals, CREB-Binding Protein, metabolism, Cell Line, Tumor, Cell Proliferation, drug effects, Cell Transformation, Neoplastic, genetics, Cyclic AMP Response Element-Binding Protein, DNA-Binding Proteins, Down-Regulation, Gene Expression Profiling, Gene Expression Regulation, Leukemic, physiology, Glycogen Synthase Kinase 3, antagonists & inhibitors, Homeodomain Proteins, Humans, Indoles, pharmacology, therapeutic use, Leukemia, Myeloid, Acute, prevention & control, Maleimides, Mice, Mice, Inbred C57BL, Models, Biological, Myeloid-Lymphoid Leukemia Protein, Neoplasm Proteins, Neoplastic Stem Cells, cytology, Oncogene Proteins, Fusion, Phosphorylation, Protein Binding, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-fos, Signal Transduction, Transcription Factors, Transcription, Genetic

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acute leukemias induced by MLL chimeric oncoproteins are among the subset of cancers distinguished by a paradoxical dependence on GSK-3 kinase activity for sustained proliferation. We demonstrate here that GSK-3 maintains the MLL leukemia stem cell transcriptional program by promoting the conditional association of CREB and its coactivators TORC and CBP with homedomain protein MEIS1, a critical component of the MLL-subordinate program, which in turn facilitates HOX-mediated transcription and transformation. This mechanism also applies to hematopoietic cells transformed by other HOX genes, including CDX2, which is highly expressed in a majority of acute myeloid leukemias, thus providing a molecular approach based on GSK-3 inhibitory strategies to target HOX-associated transcription in a broad spectrum of leukemias. Copyright 2010 Elsevier Inc. All rights reserved.

          Related collections

          Author and article information

          Comments

          Comment on this article